Microbiome company Finch Therapeutics is, officially, worth about $960 million. Shares in the company began trading publicly on Friday morning.
The company’s shares were initially priced at $17; as of 11 a.m., that price had increased by 30% to nearly $22. Finch’s stock ticker is FNCH. The company announced positive topline results from a Phase 2 trial this summer for its treatment for C. difficile, a potentially fatal gut infection that often returns even after a course of antibiotics.
Finch’s IPO is one of the most significant debuts for the nascent microbiome field, which has recovered substantially since a critical clinical trial failure in 2016 that experts believe arrested investor interest in the field.